Lumpectomy

PROCEDURE12 trials

Sponsors

Stanford University, Masonic Cancer Center, University of Minnesota, Dune Medical Devices, National Cancer Institute (NCI), Ohio State University Comprehensive Cancer Center

Conditions

Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Bilateral Breast CarcinomaBreast CancerBreast Cancer Female

Phase 2

Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

TerminatedNCT00290654

Masonic Cancer Center, University of MinnesotaBreast Cancer

Start: 2002-12-31End: 2013-03-31Updated: 2017-12-28

MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer

WithdrawnNCT00373152

Masonic Cancer Center, University of MinnesotaBreast Cancer

Start: 2005-03-31End: 2010-06-30Updated: 2017-12-05

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Active, not recruitingNCT02883062

National Cancer Institute (NCI)Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7 +1

Start: 2017-08-02End: 2026-09-11Updated: 2025-10-16

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

Active, not recruitingNCT02927912

Ohio State University Comprehensive Cancer CenterStage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer +1

Start: 2017-10-16End: 2026-11-30Updated: 2026-02-17

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Active, not recruitingNCT04266249

ECOG-ACRIN Cancer Research GroupAnatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 +6

Start: 2020-03-13End: 2038-12-31Updated: 2026-03-23

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

Active, not recruitingNCT05545150

Northwestern UniversityAnatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ +3

Start: 2022-11-28End: 2026-07-01Updated: 2025-02-07

Unknown Phase

Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer

Active, not recruitingNCT00185744

Stanford UniversityBreast Cancer, Carcinoma, Ductal

Start: 2002-09-01End: 2029-03-01Updated: 2026-03-20

MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery

CompletedNCT00749931

Dune Medical DevicesBreast Cancer

Start: 2008-10-31End: 2010-06-30Updated: 2014-06-27

Radiofrequency-Guided Localization in Patients With Abnormal Breast Tissue Undergoing Lumpectomy

WithdrawnNCT02432118

Stanford UniversityBreast Neoplasm

Start: 2015-05-31End: 2016-05-31Updated: 2017-02-02

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

RecruitingNCT03909282

Stanford UniversityDuctal Breast Carcinoma in Situ

Start: 2019-03-22End: 2026-12-01Target: 50Updated: 2026-03-12

IORT-Breast at Medical Center Navicent Health

Active, not recruitingNCT04595435

Wake Forest University Health SciencesBreast Cancer Female, Early-stage Breast Cancer

Start: 2019-03-19End: 2033-12-31Updated: 2026-01-29

Cryoablation vs Lumpectomy in T1 Breast Cancers

RecruitingNCT05505643

Washington University School of MedicineBreast Cancer, Breast Neoplasm

Start: 2024-04-03End: 2033-04-30Target: 120Updated: 2026-02-27

Related Papers

Abstract GS1-04: Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial

Clinical Cancer Research2026-02-17

Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.

Journal of Clinical Oncology2025-05-289 citations

Abstract PO3-18-11: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer

Cancer Research2024-05-02

Abstract PO5-25-11: Appropriate use of interventional cohort studies with threshold-crossing designs for de-escalation trials in breast cancer

Cancer Research2024-05-02

Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial—a study protocol

BMC Cancer2023-05-0918 citations

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN).

2023-01-0613 citations

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Clinical Cancer Research2022-11-2813 citations

Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials

The Oncologist2022-10-104 citations

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer

Cancers2022-05-2415 citations

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.

2022-05-1029 citations

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

Journal of Clinical Oncology2021-12-1062 citations

Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.

2021-07-0215 citations

Abstract PD14-09: Nci 10013 - A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC)

Cancer Research2021-02-1511 citations

Five-year results of a prospective clinical trial investigating accelerated partial breast irradiation using 3D conformal radiotherapy after lumpectomy for early stage breast cancer.

2016-06-176 citations

Breast density and the risk for positive lumpectomy margins.

Journal of Clinical Oncology2015-10-013 citations